LianBioOTC Pink - Limited Information:LIANY
- LAST PRICE0.2901
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.2901
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LIANY |
|---|---|---|
| 10:24 ET | 100 | 0.295 |
| 11:05 ET | 600 | 0.29355 |
| 02:16 ET | 3029 | 0.2901 |
| 02:59 ET | 100 | 0.2901 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LianBio | 31.3M | -0.4x | --- |
Impact Biomedical Inc | 31.3M | -7.4x | --- |
Ocean Biomedical Inc | 31.2M | -0.3x | --- |
Grace Therapeutics, Inc | 31.8M | -2.6x | --- |
ALT5 Sigma Corp | 31.8M | -0.7x | --- |
Elevation Oncology Inc | 30.9M | -0.6x | --- |
Company Information
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Contact Information
- Headquarters
- 103 Carnegie Center Drive Suite 309, Suite 215PRINCETON, NJ, United States 08540
- Phone
- 609-486-2308
- Fax
- ---
Executives
- Executive Chairman of the Board
- Konstantin Poukalov
- Interim Chief Executive Officer, Director
- Adam Stone
- Interim Chief Financial Officer
- Ehong Gu
- China General Manager
- Jiang Qian
- Chief Business Officer
- Brianne Jahn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 108.1M |
LianBio does not pay a dividend. | |
Beta | --- |
EPS | $-0.82 |
Book Value | $2.43 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
